New Italian Study Uses iCAD’s SecondLook Digital Mammography CAD Software

  New Italian Study Uses iCAD’s SecondLook Digital Mammography CAD Software

  Study results will shape National Mammography Screening Recommendations in
                                    Italy

Business Wire

NASHUA, N.H. -- November 08, 2012

iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image
analysis, workflow solutions and radiation therapy for the early
identification and treatment of cancer, announced today it has provided
SecondLook Digital^®, the company’s digital mammography Computer-Aided
Detection (CAD) software, for an Italian feasibility study.

The study, “Using computer-assisted diagnosis (CAD - Computer Aided Detection)
in the current practice of mammography screening programs,” will compare the
accuracy and cost effectiveness of conventional double reading to single
reading with CAD for mammography screenings and will enroll 45,000 patients at
six sites throughout Italy.

“This study will help us gather the necessary information to systematically
change the way we perform mammography screenings in this country. Double read
scans are outdated and cumbersome when compared to the more advanced screening
technologies available today,” said Giorgio Benea, M.D., Ospedale del Delta in
Lagosanto, Italy and Principal Investigator for the study. “Cutting-edge
technologies, like SecondLook Digital, can improve the detection of breast
cancer, allowing for earlier treatment and improved patient outcomes.”

SecondLook provides a computerized second review of mammograms. This “second”
or closer look allows radiologists to recognize subtle changes in breast
tissue that could require a more thorough examination to confirm the presence
of cancer. Additionally, SecondLook provides improved workflow for mammography
centers by enabling a radiologist to more quickly identify and review areas of
concern and work more efficiently.

“We are honored that Italy has chosen SecondLook Digital as the benchmark
technology for this important study,” said Ken Ferry, President and CEO of
iCAD. “With more than 25 published studies supporting the use of CAD in
conjunction with digital mammography, we are confident the results of the
study will help establish single read with CAD as the nationally accepted
method for mammography screening.”

About iCAD, Inc.

iCAD is an industry-leading provider of advanced image analysis, workflow
solutions and radiation therapies for the early identification and treatment
of common cancers. iCAD offers a comprehensive range of high-performance,
upgradeable CAD solutions for mammography and advanced image analysis and
workflow solutions for Magnetic Resonance Imaging, for breast and prostate
cancers and Computed Tomography for colorectal cancer. iCAD’s Xoft System,
offers radiation treatment for early-stage breast cancer that can be
administered in the form of intraoperative radiation therapy or accelerated
partial breast irradiation. The Xoft System is also cleared for the treatment
of non-melanoma skin cancer and endometrial cancer. For more information, call
877-iCADnow, or visit www.icadmed.com.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of
1995

Certain statements contained in this News Release constitute “forward-looking
statements” within the meaning of the Private Securities Litigation Reform Act
of 1995. Such forward-looking statements involve a number of known and unknown
risks, uncertainties and other factors which may cause the actual results,
performance or achievements of the Company to be materially different from any
future results, performance or achievements expressed or implied by such
forward-looking statements. Such factors include, but are not limited to, the
Company’s ability to defend itself in litigation matters, the risks relating
to the Company’s acquisition of Xoft including, the expected benefits of the
acquisition may not be achieved in a timely manner, or at all; the Xoft
business operations may not be successfully integrated with iCAD’s and iCAD
may be unable to achieve the expected synergies, business and strategic
objectives following the transaction, the risks of uncertainty of patent
protection; the impact of supply and manufacturing constraints or
difficulties; product market acceptance; possible technological obsolescence;
increased competition; customer concentration; and other risks detailed in the
Company’s filings with the Securities and Exchange Commission. The words
“believe”, “demonstrate”, “intend”, “expect”, “estimate”, “will”, “continue”,
“anticipate”, “likely”, and similar expressions identify forward-looking
statements. Readers are cautioned not to place undue reliance on those
forward-looking statements, which speak only as of the date the statement was
made. The Company is under no obligation to provide any updates to any
information contained in this release. For additional disclosure regarding
these and other risks faced by iCAD, please see the disclosure contained in
our public filings with the Securities and Exchange Commission, available on
the Investors section of our website at http://www.icadmed.com and on the
SEC’s website at http://www.sec.gov.

Contact:

iCAD
Kevin Burns, 937-431-7967
kburns@icadmed.com
or
Investor Relations:
LHA for iCAD
Anne Marie Fields, 212-838-3777 x6604
afields@lhai.com
or
Media Inquiries:
Schwartz MSL for iCAD
Helen Shik, 781-684-0770
iCAD@schwartzmsl.com
 
Press spacebar to pause and continue. Press esc to stop.